Vivos Therapeutics (VVOS) EBT Margin (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of EBT Margin data on file, last reported at 150.77% in Q1 2026.

• On a quarterly basis, EBT Margin fell 2265.0% year-over-year to 150.77% in Q1 2026; TTM through Mar 2026 was 128.36%, a 5115.0% decrease from a year earlier, with the FY2025 full-year figure at 121.71%, down 4724.0% from the prior year.
• EBT Margin for Q1 2026 stood at 150.77%, up from 181.85% in the prior quarter.
• Over the last five years, EBT Margin for VVOS reached as high as 288.39% in Q4 2023 and fell as low as 181.85% in Q4 2025.
• Historically, EBT Margin has averaged 91.48% across 5 years, with a median of 127.98% in 2022.
• Across the five-year window, EBT Margin soared 44508 bps in 2023 and slumped 36641 bps in 2024, its largest moves.
• Year by year, EBT Margin stood at 156.68% in 2022, then soared by 284 bps to 288.39% in 2023, then sank by 127 bps to 78.02% in 2024, then plunged by 133 bps to 181.85% in 2025, then increased by 17 bps to 150.77% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 150.77% in Q1 2026, 181.85% in Q4 2025, and 79.61% in Q3 2025.